Carcinogenesis Advance Access originally published online on February 28, 2008
Carcinogenesis 2008 29(5):1005-1012; doi:10.1093/carcin/bgn007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite
Hormel Institute, University of Minnesota, 801 16th Avenue Northeast, Austin, MN 55912, USA
1 United States Department of Agriculture-Agriculture Research Service, Grand Forks Human Nutrition Research Center, PO Box 9034, Grand Forks, ND 58202, USA
* To whom correspondence should be addressed. Tel: +1 507 437 9680; Fax: +1 507 437 9606; Email: jlu{at}hi.umn.edu
Methylselenol has been implicated as an active anticancer selenium (Se) metabolite. However, its in vivo efficacy against prostate cancer (PCa) has yet to be established. Here, we evaluated the growth inhibitory effects of two presumed methylselenol precursors methylseleninic acid (MSeA) and Se-methylselenocysteine (MSeC) in comparison with selenomethionine (SeMet) and selenite in DU145 and PC-3 human PCa xenografts in athymic nude mice. Each Se was given by a daily single oral dose regimen starting the day after the subcutaneous inoculation of cancer cells. We analyzed serum, liver and tumor Se content to confirm supplementation status and apoptosis indices and tumor microvessel density for association with antitumor efficacy. Furthermore, we analyzed lymphocyte DNA integrity to detect genotoxic effect of Se treatments. The data show that MSeA and MSeC exerted a dose-dependent inhibition of DU145 xenograft growth and both were more potent than SeMet and selenite, in spite of less tumor Se retention than in the SeMet-treated mice. Selenite treatment increased DNA single-strand breaks in peripheral lymphocytes, whereas the other Se forms did not. Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) and cleaved caspase-3 indices (apoptosis) from MSeC-treated tumors were higher than tumors from control mice or MSeA-treated mice, whereas the microvessel density index was lower in tumors from MSeA-treated mice. In the PC-3 xenograft model, only MSeA was growth inhibitory at a dose of 3 mg/kg body wt. In summary, our data demonstrated superior in vivo growth inhibitory efficacy of MSeA over SeMet and selenite, against two human PCa xenograft models without the genotoxic property of selenite.
Abbreviations: MSeA, methylseleninic acid; MSeC, Se-methylselenocysteine; PCa, prostate cancer; Se, selenium; SELECT, selenium-vitamin E cancer trial; SeMet, selenomethionine; SSB, single-strand break
Received August 27, 2007; revised December 20, 2007; accepted December 21, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Gundimeda, J. E. Schiffman, S. N. Gottlieb, B. I. Roth, and R. Gopalakrishna Negation of the cancer-preventive actions of selenium by over-expression of protein kinase C{varepsilon} and selenoprotein thioredoxin reductase Carcinogenesis, September 1, 2009; 30(9): 1553 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, M. J.L. Bonorden, G.-x. Li, H.-J. Lee, H. Hu, Y. Zhang, J. D. Liao, M. P. Cleary, and J. Lu Methyl-Selenium Compounds Inhibit Prostate Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate Model with Survival Benefit Cancer Prevention Research, May 1, 2009; 2(5): 484 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fairweather-Tait and R. Hurst Plasma selenium concentration and prostate cancer risk: effects are dependent on the level of exposure Am. J. Clinical Nutrition, March 1, 2009; 89(3): 927 - 928. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jiang, C. Jiang, H. Pei, L. Wang, J. Zhang, H. Hu, and J. Lu In vivo molecular mediators of cancer growth suppression and apoptosis by selenium in mammary and prostate models: lack of involvement of gadd genes Mol. Cancer Ther., March 1, 2009; 8(3): 682 - 691. [Abstract] [Full Text] [PDF]
|
|